Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial.
Hirohito Tada(Osaka City General Hospital), Toshiaki Takahashi(Okayama University), Kenji Sugio(University of Occupational and Environmental Health Japan), Hiroshige Yoshioka(Harbin Medical University), Hidetoshi Hayashi(Kindai University), Masahiro Tsuboi(National Cancer Center Hospital East), Shinji Atagi(National Institute of Technology, Nara College), Isamu Okamoto(Kyushu University Hospital), Masahiko Higashiyama(Osaka City General Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Kazuhisa Takahashi(Kansai Medical University), Tetsuya Mitsudomi(Kindai University), Noriaki Sakakura(Aichi Cancer Center), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Hidetoshi Inokawa(Ube (Japan)), Yasuo Iwamoto(Hiroshima City Asa Citizens Hospital), Morihito Okada(Hiroshima University), Takeharu Yamanaka(National Cancer Center Hospital East), Ichiro Yoshino(International University of Health and Welfare)
Cited by 24
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k